CLINICAL_TRIALS ClinicalTrials.gov record update

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04858334
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:04.574281+00:00
Published At: 2026-04-23T00:00:00+00:00
Record Updated At: 2026-04-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pancreatic Acinar Cell Carcinoma", "Pancreatic Adenosquamous Carcinoma", "Pancreatic Squamous Cell Carcinoma", "Resectable Pancreatic Acinar Cell Carcinoma", "Resectable Pancreatic Adenocarcinoma", "Resectable Pancreatic Adenosquamous Carcinoma", "Resectable Pancreatic Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-23"
protocolSection.identificationModule.nctId: "NCT04858334"
protocolSection.identificationModule.officialTitle: "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.